HLA-DRB5 and neoplasm: Two DEGs were identified for both the Group B/trastuzumab-sensitive models (tumor-specific antigens CTAG1B, MAGEC1; Supplementary Fig. S8) and the Group C/all treatment-sensitive models (HLA-DRB5, RNL5; Supplementary Fig. S8).